In other words, the average US selling price after discounts and rebates declined relative to prior quarters.
It would be of more interest if Teva broke out their unit volume because I can't see pricing leading to the negative numbers. I wouldn't think Teva's renegotiation would negate a 14.9% price increase on Jan 3rd, 2012.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.